31 июл. 2024 г. · Indications: Treatment of adult patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy, ...

Monitor patients at least daily for 10 days following CARVYKTI infusion at a certified healthcare facility for signs and symptoms of cytokine release syndrome ( ...

6 апр. 2024 г. · CARVYKTI® is now approved in the U.S. for the second-line treatment of adult patients with relapsed or refractory myeloma who have received at ...

CARVYKTI is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, ...

Carvykti is the first B-cell maturation antigen (BCMA)-targeted therapy approved for the treatment of patients with myeloma as early as first relapse.

CARVYKTI ® (ciltacabtagene autoleucel) is a treatment used for adult patients who have cancer of the bone marrow called multiple myeloma. It is used when at ... About CARVYKTI · Find a certified treatment center · Resources & Support

CARVYKTI is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least one prior therapy, including ...

Indicated for adults with relapsed or refractory multiple myeloma, after ≥1 prior line of therapy, including a proteasome inhibitor and an immunomodulatory ...

❖ Carvykti® is indicated for the treatment of adult patients with relapsed and refractory MM, who have received at least three prior therapies, including an ...